A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

October 31, 2009

Conditions
Breast Cancer
Interventions
DRUG

Gemcitabine

Gemcitabine 1000mg/m\^2 on day 1 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal

DRUG

Oxaliplatin

Oxaliplatin 100mg/m\^2 on day 2 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal

Trial Locations (1)

30322

Emory University Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Emory University

OTHER

NCT00674206 - A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter